Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etifoxine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clear Scientific Reports Topline Data for CS-1103 in Meth and Fentanyl Overdose
Details : CS-1103 is a first-in-class injectable small molecule which immediately binds to and inactivates target compounds, rapidly reversing their toxic effects and accelerating clearance into urine.
Brand Name : CS-1103
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 10, 2024
Lead Product(s) : Etifoxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etifoxine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
GABA Therapeutics commences phase I study of Etifoxine
Details : Data from this study could provide important insights for a broad range of neurological disorders beyond anxiety and depression.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2020
Lead Product(s) : Etifoxine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?